RESEARCH TRIANGLE PARK, NC--(Marketwire - December 6, 2007) - Pharmaceutical business
intelligence leader Cutting Edge Information has released a report that
suggests that the industry's best pharmacoeconomics/health outcomes groups
actually service both clinical and marketing units. "Pharmacoeconomics and
Health Outcomes: Driving Formulary Access and Reimbursement"
(
http://www.pharmacoeconomicsandhealthoutcomes.com), found that the work of
pharmacoeconomics/health outcomes personnel necessitates involvement on
both the clinical and marketing sides from the early development stages of
a product through the end of the product's lifecycle.
The key to bridging the clinical-marketing divide lies in where companies
locate their pharmacoeconomics departments. Some companies place
pharmacoeconomics groups on the commercial side of the company, locating
them closer to the internal clients that actually use their findings.
However, many pharmaceutical companies, including several firms that
participated in Cutting Edge Information's study, house their
pharmacoeconomics groups within R&D. However, although pharmacoeconomics
employees may report up through R&D, their work still crosses over into the
commercial realm. At many companies, the pharmacoeconomics team continues
to adapt its clinical/marketing balance throughout the product lifecycle.
"Wherever you locate your pharmacoeconomics group, there must be a
reporting relationship that exists across the R&D/commercial line," said
lead researcher David Richardson, a senior research analyst at Cutting Edge
Information. "This cross functional reporting line ensures that the
interests of both larger groups are served."
"Pharmacoeconomics and Health Outcomes: Driving Formulary Access and
Reimbursement," available at
http://www.pharmacoeconomicsandhealthoutcomes.com, examines eight major
pharmaceutical companies' pharmacoeconomics departments' strategies,
spending, structures and staffing. Compiled from interviews and surveys
with pharmacoeconomics directors, associate directors and executives, group
vice presidents and vice presidents of managed markets groups, the report
allows drug companies to compare and improve their own pharmacoeconomics
strategies.
The report features key graphics and metrics highlights including:
-- Pharmacoeconomics Budgets
-- Phase-to-Phase Brand-Level Pharmacoeconomics Spending
-- Departmental Monetary and Time Resource Allocations
-- Structures and Staffing
-- Departmental Funding Responsibilities
Contact Information: CONTACT:
David Richardson
+1-919-433-0216